Cardio3 BioSciences inked an agreement with Mayo Clinic that grants the company preferred access to technologies developed in the Mayo Clinic Center for Regenerative Medicine as well as other select Mayo technologies.
This agreement is an expansion of a long-standing collaboration which led to the development of C-Cure®, Cardio3 BioSciences' product candidate now in Phase III, a cell therapy based on the discovery of the cardiopoiesis platform by the team of Andre Terzic, M.D., Ph.D. at Mayo Clinic. The Mayo Clinic Center for Regenerative Medicine, led by Dr. Terzic, was designed to discover, translate, and apply regenerative technologies across medical and surgical specialties.
The two organizations have a history of working together. Three years ago, Cardio3 BioSciences established a U.S. subsidiary in Rochester, MN, to support its clinical and development activities and to bolster existing links with the Mayo Clinic and other U.S. collaborators.
In 2007, Mayo Clinic entered into a technology license agreement with Cardio3 BioSciences, giving the company an exclusive worldwide license to use the inventions related to the cardiopoiesis platform. The platform was designed to reprogram patient’s own stem cells to rebuild the heart. Researchers were able to identify a process involving a combination of growth factors to reprogram mesenchymal stems cells harvested from the bone marrow of heart failure patients into cardiac precursor cells.
